Table 1.
Baseline Patient Characteristics Prior to Transplantation
| Nonischemic, n = 35 | Ischemic, n = 28 | Indeterminate, n = 3 | P Value | |
|---|---|---|---|---|
| Age at stress testing, y | 60.0 | 59.0 | 51.0 | 0.244 |
| Age at transplant, y | 60.3 | 59.1 | 51 | 0.209 |
| Sex, n (%) | 0.838 | |||
| Male | 25 (71.4%) | 18 (64.3%) | 2 (66.7%) | |
| Female | 10 (28.6%) | 10 (35.7%) | 1 (33.3%) | |
| Follow‐up, n (%) | 0.545 | |||
| Alive | 23 (65.7%) | 18 (64.3%) | 1 (33.3%) | |
| Deceased | 12 (34.3%) | 10 (35.7%) | 2 (66.7%) | |
| Renal dysfunction, n (%) | 16 (45.7%) | 13 (46.4%) | 2 (66.7%) | 0.784 |
| Tobacco, n (%) | 13 (37.1%) | 6 (21.4%) | 1 (33.3%) | 0.412 |
| Hyperlipidemia, n (%) | 7 (20.0%) | 7 (25.0%) | 0 (0%) | 0.595 |
| Diabetes mellitus, n (%) | 22 (62.9%) | 6 (21.4%) | 2 (66.7%) | 0.003 |
| Hypertension, n (%) | 21 (60.0%) | 13 (46.4%) | 3 (100%) | 0.169 |
| Hemoglobin, g/dL | 11.4 | 11.5 | 10.4 | 0.62 |
| MELD score | 16.8 | 15.3 | 26.3 | 0.023 |
| Tbili, mg/dL | 4.24 | 2.81 | 7.63 | 0.314 |
| INR | 1.58 | 1.39 | 1.83 | 0.266 |
| Creatinine, mg/dL | 1.56 | 1.41 | 2.23 | 0.498 |
| Body mass index, kg/m2 | 30.3 | 29.7 | 29.1 | 0.919 |
| LV EF, % | 64.8 | 62.0 | 69.3 | 0.27 |
| Wall motion abnormalities, n (%) | 3 (8.6%) | 9 (32.1%) | 1 (33.3%) | 0.054 |
| LV size, n (%) | 0.133 | |||
| Normal | 34 (97.1%) | 24 (85.7%) | 2 (66.7%) | |
| Mild enlargement | 1 (2.9%) | 3 (10.7%) | 1 (33.3%) | |
| Moderate enlargement | 0 (0%) | 1 (3.6%) | 0 (0%) | |
| RV size, n (%) | 0.45 | |||
| Normal | 32 (91.4%) | 27 (96.4%) | 2 (66.7%) | |
| Mild enlargement | 3 (8.6%) | 0 (0%) | 1 (33.3%) | |
| Moderate enlargement | 0 (0%) | 1 (3.6%) | 0 (0%) | |
| RV pressure, mm Hg | 32.3 | 32.0 | 36.0 | 0.86 |
| Intrapulmonary shunt, n (%) | 6 (17.1%) | 8 (28.6%) | 1 (33.3%) | 0.52 |
Abbreviations: EF, ejection fraction; INR, international normalized ratio; LV, left ventricle; MELD, Model for End‐Stage Liver Disease; RV, right ventricle; Tbili, total bilirubin.